TOKYO — Japan issued its first approval for a COVID-19 vaccine Sunday, saying it would use the Pfizer-BioNTech shot to begin its inoculating front-line health care workers this week.
The announcement came after a government panel Friday confirmed that final results of clinical testing done in Japan showed that the vaccine had an efficacy similar to what overseas tests showed.
Many countries began vaccinating their citizens late last year, and Pfizer’s vaccine has been used elsewhere since December.
Japan has been slower than the U.S. and Europe to authorize any coronavirus vaccines, but it has also had the luxury of time. Public health measures have successfully kept infection rates low, and the country of 126 million people has recorded fewer than 7,000 COVID-19 deaths since the pandemic began.
Nevertheless, the start of vaccinations is an important development for Japan. As the number of daily new infections reached a peak of nearly 8,000 in early January, the country declared a state of emergency in Tokyo and other regions that has been extended until March 7, in part because of the appearance of new, more infectious coronavirus variants.
The number of daily new infections has declined drastically since then, with the seven-day average under 2,000, according to a New York Times database.
Read More
Health ministry official Yuta Yamashita said inoculations can start as soon as a ministry panel on vaccination logistics gives the go-ahead.
Officials plan to first vaccinate a select group of health care workers who will then administer the shots to other medical professionals.
Under the current plan, about 20,000 front-line medical workers at hospitals will get their first shots beginning around Wednesday. About 3.7 million other medical workers will be next, followed by elderly people, who are expected to get their shots in April. By June, it’s expected that all others will be eligible.
But Japan is unlikely to have its entire population vaccinated before it hosts the Olympic Games this summer, and it has said athletes and other attendees will not be required to be vaccinated beforehand.
The approval of the Pfizer shot was granted in a special fast-track process for emergency use. It took two months compared to the usual one year in a country known for cautious and slow-moving approval processes.
Still, the rollout in Japan is months behind many other countries because the government had asked for clinical testing at home in addition to the multinational tests Pfizer conducted on more than 40,000 people from July to November. Many countries accepted Pfizer’s results and moved ahead.
In a country where many people are skeptical about vaccines, Japan sought additional tests to address safety concerns. But the tests were conducted on only 160 people, and some question whether it was worth it to delay the rollout.
Japan is expected to receive 144 million doses from Pfizer, 120 million from AstraZeneca and about 50 million from Moderna before the end of this year, enough to cover its population.
Vaccines being developed by Japan are still in the early stages, so the country must rely on imports. AstraZeneca applied for approval in Japan only recently, while Moderna hasn’t applied yet. Japan’s reliance on the imports, many of them subject to EU export controls, is also causing concerns about supplies.
The New York Times and The Associated Press contributed to this report.



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.